ETON
NASDAQ
US
Eton Pharmaceuticals, Inc. - Common Stock
$24.99
▼ $-0.37
(-1.46%)
Vol 472K
7
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$453.5M
ROE
-27.9%
Margin
-9.5%
D/E
131.31
Beta
1.22
52W
$11–$23
Wall Street Consensus
9 analysts · Apr 20262
Strong Buy
6
Buy
1
Hold
0
Sell
0
Strong Sell
88.9%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 20.0%
Next Report
May 11, 2026
EPS Estimate: $0.09
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $0.09 | — | — |
| Dec 2025 | $0.09 | $0.06 | $-0.03 |
| Sep 2025 | $0.09 | $-0.07 | $-0.16 |
| Jun 2025 | $-0.04 | $-0.10 | $-0.06 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | $10.3M | $11.6M | $17.3M | $18.9M | $22.5M |
| Net Income | $627K | -$598K | -$1.6M | -$2.6M | -$1.9M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -18.6% | -18.6% | -18.6% | -18.6% | -18.6% | -27.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -13.7% | -7.1% | -7.1% | -7.1% | -7.1% | -9.5% |
| Gross Margin | 63.0% | 59.4% | 59.4% | 59.4% | 59.4% | 51.4% |
| D/E Ratio | 125.95 | 125.95 | 125.95 | 125.95 | 125.95 | 131.31 |
| Current Ratio | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 | 1.63 |
Key Ratios
ROA (TTM)
-7.3%
P/S (TTM)
6.45
P/B
14.5
EPS (TTM)
$-0.25
CF/Share
$0.12
Rev Growth 3Y
+21.4%
52W High
$23.00
52W Low
$11.09
$11.09
52-Week Range
$23.00
Financial Health
Free Cash Flow
$11.7M
Net Debt
-$6.3M
Cash
$37.1M
Total Debt
$30.8M
As of Sep 30, 2025
How does ETON compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
ETON valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
6.5
▲
30%
above
peers
(5.0)
vs Peers
vs Industry
Pricier
P/B ratio
14.5
▲
585%
above
peers
(2.1)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
ETON profitability vs Pharmaceuticals peers
ROE
-27.9%
▲
49%
above
peers
(-54.3%)
vs Peers
vs Industry
Below avg
Net margin
-9.5%
▲
80%
above
peers
(-47.4%)
vs Peers
vs Industry
Below avg
Gross margin
51.4%
▼
25%
below
peers
(68.3%)
vs Peers
vs Industry
Weak
ROA
-7.3%
▲
81%
above
peers
(-37.4%)
vs Peers
vs Industry
Top tier
ETON financial health vs Pharmaceuticals peers
D/E ratio
131.3
▲
8427%
above
peers
(1.5)
vs Peers
vs Industry
High debt
Current ratio
1.6
▼
52%
below
peers
(3.4)
vs Peers
vs Industry
Low liquidity
Beta
1.2
▲
30%
above
peers
(0.9)
vs Peers
vs Industry
More volatile
ETON fundamentals radar
ETON
Peer median
Industry
ETON profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ETON vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
RIEDEL NORBERT G
Director · Feb 03
30000 shs
Last 90 days
Top Holders
Top 5: 34.13%Opaleye Management Inc.
10.66%
$66.5M
EcoR1 Capital, LLC
7.57%
$47.2M
Blackrock Inc.
6.48%
$40.4M
Vanguard Group Inc
5.03%
$31.3M
Nantahala Capital Managemen…
4.39%
$27.3M
As of Dec 31, 2025